Synonyms: RYI-018
Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD.
| Name | Citation | CB1 | CB2 |
|---|---|---|---|
| Otenabant (CP-945598) HCl | 2 | ||
| RTICBM-189 | 0 | ||
| JD-5037 | 0 | ||
| 6-Iodopravadoline (AM630) | 2 | ||
| AM251 | 12 | ||
| Pregnenolone monosulfate sodium | 0 |
| Description |
Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD.
|
|---|
| CAS No. | 2098636-09-8 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.